Home >> Marketplace Archives >> Multigene panel testing for hereditary cancer risk, 8/17

Multigene panel testing for hereditary cancer risk, 8/17

Print Friendly, PDF & Email

 

August 2017—Myriad Genetics announced results from Study 005, a large 2,000 patient prospective study of the Myriad myRisk Hereditary Cancer test, which were featured in three poster presentations at the American Society of Clinical Oncology annual meeting in June.

Research collaborators from University of Southern California Norris Comprehensive Cancer Center and Stanford University Cancer Institute presented the data. The key findings were that more than 50 percent of the mutations identified were in patients who would not meet current testing guidelines and 34 percent of mutations were identified in unexpected genes, confirming the clinical utility of multigene panel testing to improve hereditary cancer-risk assessment.

Myriad Genetics, 801-584-3600

x

Check Also

FDA approves Myriad test as a CDx for Lynparza

Jan. 17, 2018—Myriad Genetics announced that the FDA approved BRACAnalysis CDx for use as a...

X